Comparison of enoxaparin and rivaroxaban in balance of anti-fibrinolysis and anticoagulation following primary total knee replacement: A pilot study

Medical Science Monitor

Volumn 23, Issue , 2017, Pages 704-711

  Xie, Jinwei ^a   Ma, Jun ^a   Huang, Qiang ^a   Yue, Chen ^a   Pei, Fuxing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Anticoagulants; Antifibrinolytic agents; Arthroplasty; Knee; Replacement

Indexed keywords

CEFUROXIME; CLINDAMYCIN; DICLOFENAC; ENOXAPARIN; HEMOGLOBIN; RIVAROXABAN; TRANEXAMIC ACID; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; FEMALE; HEMATOMA; HOSPITALIZATION; HSS SCORE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; OPERATIVE BLOOD LOSS; OSTEOARTHRITIS; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; SURGICAL INFECTION; TOTAL KNEE ARTHROPLASTY; VENOUS THROMBOEMBOLISM; VISUAL ANALOG SCALE; BLOOD CLOTTING; DRUG EFFECTS; DRUG INTERACTION; HEMORRHAGE; KNEE REPLACEMENT; MIDDLE AGED; PILOT STUDY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PULMONARY EMBOLISM; REHABILITATION;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD COAGULATION; DRUG INTERACTIONS; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RIVAROXABAN; TRANEXAMIC ACID; VENOUS THROMBOEMBOLISM;

EID: 85011954273     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.900059     Document Type: Article

References (33)

1. Kurtz S, Ong K, Lau E et al: Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am, 2007; 89: 780–85
2. Alshryda S, Sukeik M, Sarda P et al: A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement. Bone Joint J, 2014; 96-B: 1005–15
3. Fahmy NR, Patel DG: Hemostatic changes and postoperative deep-vein thrombosis associated with use of a pneumatic tourniquet. J Bone Joint Surg Am, 1981; 63: 461–65
4. Klenerman L, Chakrabarti R, Mackie I et al: Changes in haemostatic system after application of a tourniquet. Lancet, 1977; 1: 970–72
5. Alshryda S, Sarda P, Sukeik M et al: Tranexamic acid in total knee replacement: A systematic review and meta-analysis. J Bone Joint Surg Br, 2011; 93: 1577–85
6. Gomez-Barrena E, Ortega-Andreu M, Padilla-Eguiluz NG et al: Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: A double-blind, randomized, controlled, noninferiority clinical trial. J Bone Joint Surg Am, 2014; 96: 1937–44
7. Alshryda S, Mason J, Vaghela M et al: Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: A randomized controlled trial (TRANX-K). J Bone Joint Surg Am, 2013; 95: 1961–68
8. Huang Z, Ma J, Shen B, Pei F: Combination of intravenous and topical application of tranexamic acid in primary total knee arthroplasty: A prospective randomized controlled trial. J Arthroplasty, 2014; 29: 2342–46
9. Mont MA, Jacobs JJ: AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg, 2011; 19: 777–78
10. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012; 141: e278S–325S
11. Raveendran R, Wong J: Tranexamic acid: More evidence for its use in joint replacement surgery. Transfusion, 2014; 54: 2–3
12. Patel JN, Spanyer JM, Smith LS et al: Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: A prospective randomized study. J Arthroplasty, 2014; 29: 1528–31
13. Gross JB: Estimating allowable blood loss: corrected for dilution. Anesthesiology, 1983; 58: 277–80
14. Veen Lv, van Raay JJ, Gerritsma-Bleeker CL et al: Direct treatment comparison of DAbigatran and rivaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: Design of a randomised pilot study (DARINA). BMJ Open, 2013; 3(1): pii: e002218
15. Mangram AJ, Horan TC, Pearson ML et al: Guideline for prevention of surgical site infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control, 1999; 27: 97–132
16. Anderson FA Jr., Spencer FA: Risk factors for venous thromboembolism. Circulation, 2003; 107: I9–16
17. Izumi M, Ikeuchi M, Aso K et al: Less deep vein thrombosis due to trans-cutaneous fibular nerve stimulation in total knee arthroplasty: A randomized controlled trial. Knee Surg Sports Traumatol Arthrosc, 2015; 23(11): 3317–23
18. Reikerås O, Clementsen T: Time course of thrombosis and fibrinolysis in total knee arthroplasty with tourniquet application. Local versus systemic activations. J Thromb Thrombolysis, 2009; 28: 425–28
19. Maynard MJ, Sculco TP, Ghelman B: Progression and regression of deep vein thrombosis after total knee arthroplasty. Clin Orthop Relat Res, 1991; 273: 125–30
20. Borgen PO, Dahl OE, Reikerås O: Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis. Clin Orthop Relat Res, 2012; 470: 2591–98
21. Blanié A, Bellamy L, Rhayem Y et al: Duration of postoperative fibrinolysis after total hip or knee replacement: A laboratory follow-up study. Thromb Res, 2013; 131: e6–e11
22. Raskob GE, Hirsh J: Controversies in timing of the first dose of anticoagu-lant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest, 2003; 124: 379S–85S
23. Lieberman JR, Pensak MJ: Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am, 2013; 95: 1801–11
24. Tribout B, Colin-Mercier F: New versus established drugs in venous thromboprophylaxis: Efficacy and safety considerations related to timing of administration. Am J Cardiovasc Drugs, 2007; 7: 1–15
25. Senthil Kumar G, Von Arx OA, Pozo JL: Rate of blood loss over 48 hours following total knee replacement. Knee, 2005; 12: 307–9
26. Prasad N, Padmanabhan V, Mullaji A: Comparison between two methods of drain clamping after total knee arthroplasty. Arch Orthop Trauma Surg, 2005; 125: 381–84
27. Lin PC, Hsu CH, Chen WS et al: Does tranexamic acid save blood in minimally invasive total knee arthroplasty? Clin Orthop Relat Res, 2011; 469: 1995–2002
28. Xie J, Ma J, Kang P et al: Does tranexamic acid alter the risk of thromboembolism following primary total knee arthroplasty with sequential earlier anticoagulation? A large, single center, prospective cohort study of consecutive cases. Thromb Res. 2015; 136: 234–38
29. Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E: Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: Systematic review, meta-analysis, and indirect treatment comparisons. BMJ, 2012; 344: e3675
30. Jameson SS, Rymaszewska M, Hui AC et al: Wound complications following rivaroxaban administration: a multicenter comparison with low-molec-ular-weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Am, 2012; 94: 1554–58
31. Sindali K, Rose B, Soueid H et al: Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. Eur J Orthop Surg Traumatol, 2013; 23: 481–86
32. Castillo JM, Afanador HF, Manjarrez E, Morales XA: Non-traumatic spontaneous spinal subdural hematoma in a patient with non-valvular atrial fibrillation during treatment with rivaroxaban. Am J Case Rep, 2015; 16: 377–81
33. Yen SH, Lin PC, Kuo FC, Wang JW: Thromboprophylaxis after minimally invasive total knee arthroplasty: A comparison of rivaroxaban and enoxaparin. Biomed J, 2014; 37: 199–204